DCVAC/OvCa and Standard of Care (SoC) in Relapsed Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma

Inclusion Criteria: * Histologically confirmed high-grade serous or endometrioid carcinoma of the ovary, peritoneum or fallopian tube. * Without disease progression during preceding platinum-based chemotherapy * Platinum-sensitive patients defined as Platinum-Free Interval of more than 6 months between the end of the last cycle of platinum-based chemotherapy and radiologic evidence of progression. * First relapse identified by the criteria above up to 28 days prior to study randomization * Eastern Cooperative Oncology Group (ECOG) performance status 0-1 * Known BRCA (breast cancer susceptibility gene) mutation status before randomization * Patient is intended to be treated with bevacizumab, best supportive care (BSC) only or PARPi Exclusion Criteria: * Tumor-specific: any other histology sub-type that is not high grade serous or endometrioid, however a combination of these is allowed * Disease Treatment history: started or ongoing systemic treatment for current relapse of Epithelial Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer before signing informed consent form (ICF), concomitant use of anti-neoplastic anti- hormonal therapy * Intention to treat with intra-peritoneal chemotherapy